Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
& van de Laar, A
G.BessonJ
Epilepsy Behav Rep
Key Phase 3 trials include: TRIUMPH-1: Retatrutide for obesity without type 2 diabetes TRIUMPH-2: Retatrutide for type 2 diabetes TRIUMPH-3: Retatrutide for obesity with type 2 diabetes TRIUMPH-4: Retatrutide for metabolic dysfunction-associated steatohepatitis (MASH) Results from these trials are expected between 2025 and 2027
Cellular Technology Limited)
US$ 20.82
US$ 21.20
US$ 23.16
US$ 27.42
US$ 21.01
US$ 20.28
US$ 25.33
US$ 27.91
